| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 77% leaning bullish and 22% bearish. Among these notable options, 4 are puts, totaling $495,628, and 5 are calls, amounting to $213,111.
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $68.0 for Gilead Sciences during the past quarter.
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Gilead Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Gilead Sciences's significant trades, within a strike price range of $50.0 to $68.0, over the past month.
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| GILD | PUT | TRADE | BEARISH | 01/16/26 | $10.5 | $7.1 | $9.2 | $67.50 | $367.9K | 162 | 400 |
| GILD | PUT | TRADE | BULLISH | 01/16/26 | $3.0 | $2.81 | $2.81 | $50.00 | $70.2K | 662 | 254 |
| GILD | CALL | SWEEP | BULLISH | 06/21/24 | $1.49 | $1.43 | $1.49 | $67.50 | $59.7K | 405 | 556 |
| GILD | CALL | SWEEP | BULLISH | 05/17/24 | $0.51 | $0.46 | $0.51 | $68.00 | $51.1K | 2.2K | 1.0K |
| GILD | CALL | SWEEP | BULLISH | 06/21/24 | $2.63 | $2.59 | $2.62 | $65.00 | $36.5K | 283 | 292 |
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
5 market experts have recently issued ratings for this stock, with a consensus target price of $82.2.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with Benzinga Pro for real-time alerts.
Posted In: GILD
